CROs offering Specialized & Large-Animal Models with Peptide
8 published
8 published CROs match Specialized & Large-Animal Models and Peptide.
Locations in this set include United States, China, India, Australia, Denmark, and Italy.
Capabilities that show up most often in this set: GLP Toxicology, In Vitro ADME / DMPK, In Vitro Pharmacology, In Vivo PK / PD Studies, and Preclinical In Vitro Studies.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Creative BioarrayCreative Bioarray provides preclinical research solutions including drug screening, ADME-PK, toxicity studies, and cell-based services across oncology, neurology, cardiovascular, and metabolic therapeutic areas.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/specialized-animal-models/peptide.md